Completed
Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma
NCT05517330
- Conditions
- Head and Neck Cancer, Head and Neck Neoplasms, Neoplasms, +1 more
- Locations
-
- Xingchen Peng Chengdu, Sichuan, China